AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Ceramides, Cardiovascular Risk After Acute Coronary Syndrome, and the Effect of PCSK9 Inhibition with Alirocumab
By Schwartz G, Szarek M, Halme M et al.
Background: Ceramides are lipid species comprising sphingosine and fatty acid moieties carried by lipoprotein particles and influencing their function. CERT2 is a score (0 to 12 points) derived from concentrations and ratios of several ceramide and phospholipid species. CERT2 has been shown to predict the risk of major adverse cardiovascular events (MACE) in patients with stable coronary heart disease or with acute coronary syndrome (ACS) within 1 month. However, shortly after ACS ceramides may be perturbed by an acute phase response and lipid-lowering therapy may be in flux. Research Question: It is not known whether CERT2 predicts MACE and death independent of conventional risk factors and biomarkers in patients stabilized after ACS on intensive lipid-lowering therapy. We addressed this question in a post hoc analysis of the ODYSSEY OUTCOMES trial that compared PCSK9 inhibitor alirocumab with placebo, each added to optimized statin therapy. Methods: At baseline 1-12 (median 2.6) months after ACS, ceramides and phospholipids were measured by mass spectrometry and CERT2 was calculated in 4285 trial participants. Natural cubic splines adjusted for age, sex, diabetes, estimated glomerular filtration rate, LDL cholesterol, lipoprotein(a), and high-sensitivity C-reactive protein related CERT2 to 4-year risks of MACE (cardiovascular death, myocardial infarction, ischemic stroke, unstable angina, and ischemia-driven coronary revascularization) and all-cause death. Results: In the placebo group, CERT2 predicted both MACE ( Figure left ; P=0.012) and death ( Figure right ; P=0.004) independent of key demographic and clinical risk factors. Alirocumab significantly reduced CERT2 by approximately 2 risk-score points compared with placebo at 4-month follow-up. In the alirocumab group, higher baseline CERT2 was no longer associated with MACE (P=0.49) or death (P=0.13). Conclusion: In patients stabilized after ACS on optimized statin treatment, CERT2 predicts the risk of MACE and death independent of conventional clinical characteristics and biomarkers. Alirocumab significantly lowered CERT2 and CERT2-associated risk was attenuated in the alirocumab group, thus indicating that intensive lipid-lowering therapy with a PCSK9 inhibitor may modify ceramide-associated residual risk.